209528-69-8

Basic information

• Product Name: Methyl 3-(benzyloxy)-4-nitrobenzoate
• Synonyms: Methyl 3-(benzyloxy)-4-nitrobenzoate;2-(Benzyloxy)-4-(methoxycarbonyl)nitrobenzene;Methyl 3-(benzyloxy)
• CAS NO: 209528-69-8
• Molecular Formula: C₁₅H₁₃NO₅
• Molecular Weight: 287.26742
• Mol File: 209528-69-8.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 3-(benzyloxy)-4-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-(benzyloxy)-4-nitrobenzoate(209528-69-8)
• EPA Substance Registry System: Methyl 3-(benzyloxy)-4-nitrobenzoate(209528-69-8)

Safety Data

• Hazardous Substances Data: 209528-69-8(Hazardous Substances Data)

Usage

General Description

Methyl 3-(benzyloxy)-4-nitrobenzoate is a synthetic organic compound belonging to the class of benzoate esters. It is a derivative of benzoic acid with a methyl group, a benzyloxy group, and a nitro group attached to the benzene ring. Methyl 3-(benzyloxy)-4-nitrobenzoate is commonly used in the field of organic synthesis and pharmaceutical research as a building block for the production of various chemicals and drugs. It is known for its potential applications in the development of novel compounds with biological activities and pharmacological properties. Additionally, it is important to handle this chemical with care and in accordance with proper safety protocols due to its potential hazards.

Upstream product

• 713-52-0 methyl 3-hydroxy-4-nitrobenzoate 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 

Downstream Products

• 475215-88-4 methyl 4-amino-3-(benzyloxy)benzoate 
• 881909-58-6 methyl 4-amino-3-benzyloxy-5-bromobenzoate 
• 881909-62-2 methyl 3-ethyl-7-[(phenylmethyl)oxy]-1H-indole-5-carboxylate 
• 911369-89-6 methyl 3-benzyloxy-5-bromo-4-[(trifluoroacetyl)amino]benzoate 
• 881909-60-0 methyl 3-bromo-4-[(2E,Z)-2-buten-1-yl(trifluoroacetyl)amino]-5-[(phenylmethyl)oxy]benzoate 
• 14617-29-9 4-nitro-3-phenylmethoxybenzoic acid 
• 1379520-51-0 methyl 3-(benzyloxy)-4-(3-benzyloxy-4-nitrobenzamido)-benzoate 
• 1069130-70-6 methyl 3-benzyloxy-4-(4-methoxyphenylamino)benzoate 
• 1069130-72-8 1-benzyloxy-6-methoxy-3-methyl-9H-carbazole 
• 1388805-41-1 1-benzyloxy-3-(1-benzyloxy-3-hydroxymethyl-6-methoxy-9H-carbazol-9-yl)methyl-6-methoxy-9H-carbazole 
• 1069130-73-9 1-benzyloxy-3-hydroxymethyl-6-methoxy-9H-carbazole 
• 1069130-74-0 1-benzyloxy-3-formyl-6-methoxy-9H-carbazole 
• 182261-94-5 clausine I 
• 1096900-80-9 4-amino-3-(benzyloxy)benzoic acid 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING

Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or amyloid formation in the peripheral nerves, kidney, cardiac tissue, eye and CNS, and of treating a subject with peripheral TTR amyloidosis.

Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors

ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes of antibacterial drugs that are unrepresented in the antibacterial pipeline. We developed 32 new N-phenylpyrrolamides and evaluated them against DNA gyrase and topoisomerase IV from E. coli and Staphylococcus aureus. Antibacterial activities were studied against Gram-positive and Gram-negative bacterial strains. The most potent compound displayed an IC50 of 47 nm against E. coli DNA gyrase, and a minimum inhibitory concentration (MIC) of 12.5 μm against the Gram-positive Enterococcus faecalis. Some compounds displayed good antibacterial activities against an efflux-pump-deficient E. coli strain (MIC=6.25 μm) and against wild-type E. coli in the presence of efflux pump inhibitor PAβN (MIC=3.13 μm). Here we describe new findings regarding the structure–activity relationships of N-phenylpyrrolamide DNA gyrase B inhibitors and investigate the factors that are important for the antibacterial activity of this class of compounds.

GLP-1 receptor agonist compounds having stabilized regions

The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.